BrainsWay Balance Sheet Health
Financial Health criteria checks 6/6
BrainsWay has a total shareholder equity of $44.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $72.1M and $28.1M respectively. BrainsWay's EBIT is $1.1M making its interest coverage ratio -1.3. It has cash and short-term investments of $48.1M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -1.3x |
Cash | US$48.13m |
Equity | US$44.03m |
Total liabilities | US$28.07m |
Total assets | US$72.10m |
Recent financial health updates
No updates
Recent updates
BrainsWay: Cash Flow Doubts Weigh On The Stock
Nov 13BrainsWay: Operating Leverage Driving Upside
Aug 13BrainsWay: An Interesting Niche Concern
Jul 22BrainsWay: Profitable, Growing, And Cheap
Mar 07BrainsWay Q4 Earnings Preview
Feb 27BrainsWay gets significant private insurance coverage from Cigna for OCD treatment Utilizing Deep TMS
Sep 14BrainsWay adds 20% on FDA nod for depression therapy
Aug 29Brainsway GAAP EPS of -$0.07 in-line, revenue of $8.01M misses by $0.41M
Aug 10BrainsWay's Shares Look Attractive
Jul 12BrainsWay's Competitive Advantage Is Growing
Jan 21BrainsWay: Still Undervalued (Still)
Jun 02BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment
Apr 26Brainsway: Still Undervalued
Dec 24Brainsway +4% on Q3 beat, bottom-line up 66%
Nov 18Financial Position Analysis
Short Term Liabilities: BWAY's short term assets ($57.3M) exceed its short term liabilities ($12.7M).
Long Term Liabilities: BWAY's short term assets ($57.3M) exceed its long term liabilities ($15.4M).
Debt to Equity History and Analysis
Debt Level: BWAY is debt free.
Reducing Debt: BWAY had no debt 5 years ago.
Debt Coverage: BWAY has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BWAY has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/21 03:02 |
End of Day Share Price | 2025/01/21 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BrainsWay Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kyle Mikson | Cantor Fitzgerald & Co. |
Raghuram Selvaraju | H.C. Wainwright & Co. |
Jeffrey Cohen | Ladenburg Thalmann & Company |